Overview

Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia

Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the efficacy, safety and tolerability of two dosing schedules of LDE225 in patients with relapsed/refractory acute leukemia or elderly patients with untreated acute leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals